The knockdown of hnRNPK abolished changes in the biological features of NB cells induced by pancEts-1, which indicates that the pancEts-1/hnRNPK/β-catenin axis may be of potential value as a novel therapeutic target for NB. This evidence concerns the gene HNRNPK and neuroblastoma.